QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.117226v1 321/2/726    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pellequer, Y. Articles by Lamprecht, A. Search for Related Content PubMed PubMed Citation Articles by Pellequer, Y. Articles by Lamprecht, A.

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Epithelial Heparin Delivery via Microspheres Mitigates Experimental Colitis in Mice

Laboratory of Pharmaceutical Engineering, Faculty of Medicine and Pharmacy, University of Franche-Comté, Besançon, France (Y.P., A.L.); Laboratory of Biopharmaceutics, Saarland University, Saarbrücken, Germany (Y.M.); and Institut National de la Santé et de la Recherche Médicale, U734-EA 3452, Faculty of Pharmacy, University H. Poincaré, Nancy, France (N.U.)

Low-molecular-weight heparins (LMWH) have been shown to be efficient in the treatment of inflammatory bowel disease (IBD). Parenteral heparin therapy, however, may cause hemorrhagic adverse effects. To reduce this risk, epithelial LMWH delivery in combination with a system ensuring selective drug release to the inflamed tissue was tested here. Enoxaparin loaded microspheres (MS) were administered orally to male BALB mice suffering from a pre-existing experimental colitis, whereas control groups received subcutaneous or rectal LMWH solution. Colon weight/length index and alkaline phosphatase and myeloperoxidase activities were assessed to determine the inflammation. Tissue penetration experiments elucidated the processes involved in the proposed new therapeutic approach. Oral LMWH-MS proved to be equally efficient in mitigating experimental colitis as rectally administered LMWH solution when quantified by myeloperoxidase activity (MS, 10.2 ± 1.5 U/mg tissue; rectal, 9.2 ± 1.6 U/mg) and to be superior to subcutaneous LMWH (s.c., 21.6 ± 5.6 U/mg; untreated colitis control, 30.0 ± 3.8 U/mg). Pharmacokinetic studies found a notably low systemic availability of oral LMWH delivered from MS (<5%) indicating a low potential for adverse effects. The tissue permeability was selectively enhanced in the inflamed regions where a 9-fold higher LMWH penetration was found compared with healthy tissue. Epithelial LMWH delivery has been found a promising anti-inflammatory therapeutic approach. The use of LMWH-MS in this context offers a promising tool for IBD therapy by enhancing specifically drug availability at inflamed tissue sites while reducing the risk for systemic adverse effects to a negligibly low level.

Address correspondence to: Dr. Alf Lamprecht, Laboratory of Pharmaceutical Engineering, Faculty of Medicine and Pharmacy, University of Franche-Comté, Place Saint Jacques, 25000 Besançon, France. E-mail: alf.lamprecht{at}univ-fcomte.fr